Hengrui Pharma's HRS-5965 Capsule Drug Application Accepted for Review

Hengrui Pharma Receives NMPA Clearance for Clinical Trials of SHR-1819 and SHR-1905 Injections in Atopic Dermatitis

Wellington Management Increases Stake in Hengrui Pharma by 49,600 Shares

Wellington Management Increases Stake in Hengrui Pharma by 49,600 Shares at HK$66.13 Each

Jiangsu Hengrui Pharmaceuticals - Nmpa Approves Self-Developed Class 1 Innovative Drug, Hetrombopag Olamine Tablets, for Adding a New Indication

China NMPA approves Hengrui’s Hetrombopag Olamine tablets for new SAA indication

Hengrui Pharma Receives Regulatory Clearance for Clinical Trial of Irinotecan Liposome Injection

Hengrui Pharma's Innovative Drug Hetrombopag Olamine Tablets Gain Additional Indication

Alphamab Oncology appoints Wang Hongwei as chief technology officer

China Stocks Rise on Hopes for End to Middle East Crisis; CATL Jumps 5% on Higher Profit

Hengrui Pharma Subsidiary Receives Approval for Adebeli Monoclonal Antibody Clinical Trial

Hengrui Pharmaceuticals Obtains Nod for Lung Cancer Combo Drug Trials

HENGRUI PHARMA Subsidiary Receives Clinical Trial Approval for Drug Candidate HRS-1780 Tablets

HENGRUI PHARMA Repurchases 630,000 A Shares for 33.98 Million Yuan on March 3

HENGRUI PHARMA Announces Board of Directors Restructuring

Jiangsu Hengrui Medicine files HKEX next-day disclosure return for 623,000-share repurchase at RMB 54.83 per share

Hengrui Pharma Allocates 15.63 Million Yuan for Share Buyback on February 26

Jiangsu Hengrui Medicine files HKEX next-day disclosure return announcing 276,000-share repurchase at RMB 56.63 per share

Hengrui Pharma's Novel Drug SHR-1918 Injection Receives Marketing Application Acceptance and Priority Review Status

Hengrui Pharma's Innovative Drug HRS-5346 for Elevated Lipoprotein(a) Levels Added to Breakthrough Therapy List